At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Mezagitamab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Mezagitamab, Pomalidomide, and 1 other intervention for Relapsed/Refractory and Multiple Myeloma. Completed, enrolled 50 participants across 7 sites.
Detailed Summary
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed/Refractory, Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionJan 2022
TodayJul 2026
First PostedFeb 20, 2018
Enrollment StartApr 20, 2018
Primary CompletionJan 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.4 years ago
Interventions
Mezagitamabdrug
Mezagitamab subcutaneously.
Pomalidomidedrug
Pomalidomide orally.
Dexamethasonedrug
Dexamethasone orally.